参芪扶正注射液联合化疗治疗血液恶性肿瘤患者的疗效及对造血和免疫的影响

Effects of Shenqi Fuzheng Injection with Chemotherapy on Hematopoiesis and Immune Function of Patients with Hematological Malignancy

目的:探究参芪扶正注射液联合化疗治疗血液恶性肿瘤的疗效及对患者造血及免疫功能的影响。方法:选取2015年7月至2017年2月无锡市第五人民医院肿瘤科收治的血液恶性肿瘤患者113例,按照随机数字表法随机分为对照组(n=56)和观察组(n=57),2组患者均采用常规化疗方案进行治疗,观察组在对照组的基础上联合参芪扶正注射液治疗,连续治疗1个月。统计2组患者临床疗效;检测并比较治疗前后2组患者造血功能及T淋巴细胞免疫、红细胞免疫功能的变化。结果:观察组缓解率为91.23%,较对照组的76.79%显著升高(P<0.05);与治疗前比较,治疗后2组患者外周血白细胞显著降低(P<0.05),红细胞、血小板及血红蛋白(Hb)水平显著升高(P<0.05),且2组间差异有统计学意义(P<0.05);与治疗前比较,治疗后2组CD4+T淋巴细胞比例及CD4+/CD8+均显著降低,但治疗后观察组均显著高于对照组(P<0.05);治疗后对照组CD8+T淋巴细胞比例有所升高,观察组有所降低,但治疗前后差异均无统计学意义(P>0.05),且观察组CD8+T淋巴细胞比例显著低于对照组(P<0.05);与治疗前比较,治疗后观察组红细胞C3b受体花环率(RBC-C3bRR)及肿瘤细胞花环率(TRR)明显升高(P<0.05),免疫复合物花环率(RBC-ICRR)明显降低,且2组间差异有统计学意义(P<0.05)。结论:参芪扶正注射液可有效保护血液恶性肿瘤化疗患者的造血功能及免疫功能,有效提高其临床疗效。

Objective： To explore the clinical efficacy of Shenqi Fuzheng Injection combined with chemotherapy on hematological malignancy and the effects on hematopoiesis and immune function in patients. Methods： A total of 113 patients with hematological malignancy treated in Department of Oncology of Fifth People′s Hospital of Wuxi City from July 2015 to February 2017 were selected and divided into control group and observation group according to the random number table method,with 56 cases in control group and 57 cases in observation group.Both groups were treated with conventional chemotherapy methods,and the observation group was additionally given Shenqi Fuzheng Injection on the basis of this group for 2 month.The clinical efficacy of both groups was statistically analyzed,and the changes of hematopoiesis function,T lymphocyte immune and RBC immune function indexes were detected and compared. Results： The remission rate of observation group was 91.23%,which was higher than 76.79% of control group （ P 〈0.05）.Compared with before treatment,the peripheral blood WBC of both groups decreased significantly after treatment （ P 〈0.05）,and the RBC,PLT and Hb contents increased significantly after treatment （ P 〈0.05 or P 〈0.01）,and the difference between the two groups was statistically significant （ P 〈0.01）.Compared with before treatment,the proportions of CD4 ＋ T lymphocyte and CD4 ＋/CD8 ＋ of both groups were decreased significantly,but observation group decreased more than control group （ P 〈0.01）,and the proportion of CD8 ＋ T lymphocyte of control group increased while observation group decreased,but the difference was not significant （ P 〉0.05）,and the proportion of CD8 ＋ T lymphocyte of observation group was lower than control group （ P 〈0.01）.Compared with before treatment,the RBC-C3bRR and TRR of observation group significantly were increased after treatment （ P 〈0.01） but the RBC-ICR was decreased significantly,and the difference of 2 groups was significant （ P 〈0.01）. Conclusion： Shenqi Fuzheng Injection can effectively protect the hematopoiesis and immune function of patients with hematological malignancy effectively,and increase the clinical efficacy significantly.